Skip to main content
PMC home page
Acta Pharmacologica Sinica logoLink to Acta Pharmacologica Sinica
. 2009 Sep 14;30(10):1415–1420. doi: 10.1038/aps.2009.133

Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage

Shun-ying Hu 1, Hai-feng Duan 2, Qing-fang Li 2, Yue-feng Yang 2, Jin-long Chen 2, Li-sheng Wang 2, Hua Wang 2,*
PMCID: PMC4007330  PMID: 19749787

Abstract

Aim:

To investigate the effect of HGF on proliferation, apoptosis and migratory ability of human vascular endothelial cells against gamma ray irradiation.

Methods:

ECV304 cells derived from adult human umbilical vein endothelial cells (HUVEC) were irradiated with a single gamma ray dose of 20 Gy. Immunocytochemistry and Western blot analysis were used to detect c-Met protein expression and HGF/c-Met signal pathway. In the HGF-treated groups, ECV304 cells were incubated with HGF (20 or 40 ng/mL) 3 h prior to irradiation. At 48 h post-irradiation, the proliferation of ECV304 cells was measured by MTT assay, the apoptosis was assessed by flow cytometry, and the migratory ability of ECV304 cells was measured by transwell chamber assay.

Results:

c-Met protein is expressed in ECV304 cells and can be activated by HGF. Gamma ray irradiation inhibits proliferation and migration of ECV304 cells in a dose-dependent manner. HGF significantly promoted the proliferation of ECV304 cells, and flow cytometry revealed that HGF can inhibit apoptosis of ECV304 cells. Transwell chamber assay also showed that HGF increases migration activity of endothelial cells.

Conclusion:

HGF may afford protection to vascular endothelial cells against gamma ray irradiation-induced damage.

Keywords: hepatocyte growth factor, endothelial cell, irradiation-induced damage, proliferation, apoptosis, migration

Introduction

Radiation-induced heart disease (RIHD) is a particular problem related to radiation treatments for the mediastinum and breast, such as in lymphoma, breast cancer, esophagogastric cancer, thymoma and lung cancer1. The goal of radiotherapy is to deliver a dose to the tumor that is sufficient to provide a high probability of cure yet will cause minimal damage to the surrounding tissues. During radiotherapy of tumors adjacent to the heart, at least a portion of the heart is frequently included in the treatment field and may receive the full dose intended for the tumor. Local heart irradiation with single or fractionated doses leads to heart failure following dose-dependent latency periods2. High survival rates of diseases and long follow-up time of relatively young patients revealed that irradiation of the heart can cause chronic impairment of cardiac pump function and cardiac disease3, 4, 5, 6. There is compelling epidemiological evidence that the risk of dying from myocardial infarction or another ischemic heart disease is significantly increased at more than 10−15 years after exposure of the heart to local irradiation7.

Radiation-induced damage to the microvasculature has severe pathological implications for kidney, heart and other tissues8, 9, 10. The most significant type of radiation-induced heart disease (RIHD) appears to be myocardial damage, which may result from loss of alkaline phosphatase activity of capillary endothelial cells 6−10 weeks after radiotherapy9, 11. After a single dose of 20 Gy, myocardial degeneration becomes apparent in rats at approximately 6 months post-irradiation and is preceded by a marked reduction in capillary density12. In addition to myocardial degeneration, perivascular and interstitial fibrosis are seen13. Parallel to the development of morphological damage, hemodynamic studies reveal a marked impairment of cardiac function14, 15. It has been proposed that effective pharmacological intervention to protect the vascular system could lead to a decrease in normal tissue damage.

Hepatocyte growth factor (HGF), originally identified and cloned as a potent mitogen for mature hepatocytes16, 17, 18, has mitogenic, morphogenic, and anti-apoptotic activities in a wide variety of cells, preferentially in most epithelial and endothelial cells19, 20, 21. It is particularly important that HGF enhances regeneration of organs such as liver, kidney and lung20. Additionally, HGF has angiogenic activity22, 23, 24.

However, whether HGF is effective in protecting vascular endothelial cells against gamma ray irradiation has not been reported. The purpose of this study was to investigate the effect of HGF on proliferation, apoptosis and migration of human vascular endothelial cells irradiated with a single dose of gamma rays.

Materials and methods

Cell lines and cell culture

ECV304 cells derived from adult human umbilical veins endothelial cells (HUVEC) were cultured in DMEM (Gibco, USA) that included 10% newborn calf serum (Gibco). The medium contained penicillin and streptomycin. Cells were incubated at 37 °C in 5% CO2.

Immunocytochemistry

Immunocytochemistry was used to examine expression of c-Met in the ECV304 cells. Either polyclonal rabbit anti-human c-Met IgG or the negative control of normal rabbit immunoglobulin was used as the primary antibody, and HRP-linked goat anti-rabbit IgG was used as the secondary antibody (Santa Cruz, CA, USA). Cells were visualized by a single observer with a microscope at 100×magnification.

Western blot analysis

To prepare lysates, cells were washed in PBS and solubilized with 50 mmol/L Hepes solution (pH 7.4) containing 1% (v/v) Triton X-100, 4 mmol/L EDTA, 1 mmol/L sodium fluoride, 0.1 mmol/L sodium orthovanadate, 1 mmol/L tetrasodium pyrophosphate, 2 mmol/L phenylmethylsulfonyl fluoride (PMSF), 10 μg/mL leupeptin, and 10 μg/mL aprotitin. Following centrifugation in a microfuge, the protein concentration in the supernatant was determined. Equal protein levels of cell lysates were electrophoresed through reducing SDS polyacrylamide. Completion of the protein transfer from gels to the membranes was checked by staining the gels with Coomassie Blue R-250. The membranes were blocked with 5% nonfat milk and incubated with antibodies for c-Met and phospho-specific c-Met. Levels of proteins and phospho-proteins were detected with HRP-linked secondary antibodies and the ECL system. Membranes were stained with Coomassie Blue to confirm that there was equal loading and transfer.

Irradiation procedure

Twenty-four h before irradiation, cell cultures received fresh culture medium. Cells were then irradiated at room temperature with a single dose of 20 Gy, operated at a dose-rate of 510.4 cGy/min. Sham-irradiated cell cultures were included at room temperature at the same time. After irradiation, cell cultures were replaced in the incubator and were maintained at 37 °C under 5% CO2 .

Mitogenicity bioassay (MTT test)

A total of 200 μL ECV304 cells were seeded separately into 96-well plates at a density of 1×106 cells per well. On d 3, the cells were irradiated with a single dose of 5, 10, and 20 Gy, respectively. At 48 h post-irradiation, 20 μL MTT (5 mg/mL) was added to each well. The cells were cultured for an additional 4 h, and then all the liquid in each well was tipped out. To dissolve the precipitate, 150 μL DMSO was added. Absorbance at 570 nm was determined by ELISA spectrometry.

Apoptosis assay by flow cytometry

Flow cytometric assays for detection of apoptosis were carried out using the Annexin V kit (Caltag Laboratories) according to the manufacturer's protocol. Briefly, trypsinized cells were resuspended in binding buffer with Annexin V-FITC and propidium iodide (PI) and incubated for 15 min in the dark. Flow cytometry was performed immediately after the staining was completed. All analyses were performed on a Becton Dickinson flow cytometer, and the data were processed using the Cell Quest program.

Transwell chamber assay

The motility and invasive ability of ECV304 cells were performed in 24-well transwell plates. The upper surface of polycarbonate filters with 8 mm pores was coated with collagen I. ECV304 cells were pre-incubated with different concentrations of HGF or 1% BSA (negative control) for 24 h at 37 °C in a CO2 incubator and then detached and resuspended in serum-free DMEM. A suspension of cells (2×105 cells/100 μL) was placed in the upper chambers, and the lower chambers were filled with 600 μL of DMEM medium. Cells were allowed to migrate for 4 h at 37 °C. Migration was terminated by removing the cells from the upper compartment of the filter with a cotton swab. Cells that had invaded through the collagen I and reached the lower surface of the filter were quantified by counting the cells that migrated in five random microscopic fields per filter at 100×magnification (Olympus IX51; Olympus Corporation, Tokyo, Japan).

Statistical analysis

All statistical analyses were performed using SPSS10.0 for Windows (SPSS Inc, USA).

Continuous variables were expressed as mean±standard deviation (SD), and the differences were evaluated by one-way analysis of variance (ANOVA) or t test.

Results

c-Met protein is expressed in ECV304 cells and can be activated by HGF

To determine whether ECV304 cells express c-Met and whether HGF can activate signal transduction in ECV304 cells, we evaluated the expression of c-Met and phosphor-specific c-Met protein in ECV304 cells. Immunocytochemistry analysis showed ECV304 cells expressed c-Met (receptor of HGF) (Figure 1A). Further, immunoprecipitation followed by Western blot analysis, using antibodies for phosphor-tyrosine and c-Met, revealed that HGF elicited tyrosine phosphorylation of c-Met in ECV304 cells (Figure 1B).

Figure 1.

Figure 1

Open in a new tab

c-Met protein expression and phosphorylation in ECV304 cells. (A) The ECV304 cells were immuocytochemically stained with control antibody(a) and antibody against c-Met(b) (original magnification: 100×). (B) ECV304 cells were treated with HGF at concentrations indicated for 30 min and harvested for immunoprecipitation using c-Met antibody-protein A-agarose conjugates followed by Western blot with phosphotyrosine specific antibody (top: designated as Py-c-Met). Blots were stripped and reported with antibody to c-Met (bottom).

Gamma ray irradiation effects on proliferation, apoptosis and motility of ECV304 cells is dose dependent

Gamma rays can cause the decline of viable cells and inhibit cell proliferation. We detected the proliferation and apoptosis of ECV304 cells using MTT assay and flow cytometry 48 h after irradiation with single dose of 5, 10, and 20 Gy of gamma rays, respectively. As shown in Figure 2A, the proliferation of ECV304 cells were inhibited after a single irradiation with gamma rays, but irradiation aggravated apoptosis of ECV304 cells and was dose-dependent manner (Figure 2B).

Figure 2.

Figure 2

Open in a new tab

Gamma ray irradiation induces the apoptosis and inhibits proliferation and motility of ECV304 cells. (A) MTT assay shows That gamma ray irradiation inhibits proliferation of ECV304 cells in a dose-dependent manner. (B) Apoptosis assay with flow cytometry shows irradiation increases apoptosis of ECV304 cells. (C and D) Depression of ECV304 cell invasion and migration induced by gamma ray irradiation. Typical micrographs of invading ECV304 cells (C) (original magnification: 200×). Irradiation decreased rates of cell invasion significantly in a dose dependent manner (D). 0 Gy: sham-irradiated, 5 Gy: irradiated with 5 Gy gamma ray, 10 Gy: irradiated with 10 Gy gamma ray, 20 Gy: irradiated with 20 Gy gamma ray. bP<0.05, cP<0.01 vs without irradiation.

Further, 48 h post-irradiation, we evaluated the motility and invasive ability of ECV304 cells migrating through collagen I coated membrane. Migrated cells were treated with irradiation of a single dose gamma ray of 5, 10, and 20 Gy, respectively. At 48 h post-irradiation, cells were placed on collagen I-coated filters and incubated for 4 h for migration assay. They were then fixed, stained with 0.5% crystal violet and photographed. The number of cells passing through the filter was counted after staining with crystal violet. The transwell chamber assay showed that the migration ability of ECV304 cells was significantly decreased following a single dose of gamma rays and was dose dependent. The numbers of cells migrating across the collagen I coated membrane were significantly decreased compared to control cells (Figure 2C–2D).

HGF protects ECV304 against gamma ray irradiation induced damage

To determine whether HGF protects ECV304 cell against irradiation, cells were incubated with HGF with a dose of 0, 20, or 40 ng/mL 3 h prior to irradiation with 20 Gy of gamma ray. At 48 h post-irradiation, the proliferation, apoptosis and migration ability of ECV304 cells were measured. MTT assay confirmed that the proliferation of cells with HGF was decreased compared to sham-irradiated cells, but proliferation was increased significantly compared to irradiated cells without HGF (Figure 3A). Apoptosis analysis with flow cytometry showed that HGF inhibited the apoptosis of irradiated ECV304 cells (Figure 3B).

Figure 3.

Figure 3

Open in a new tab

HGF protects ECV304 cells against irradiation of 20 Gy of gamma ray irradiation. (A) Proliferation of cells with HGF (40 ng/mL) was significantly increased compared to cells without HGF. (B) HGF attenuates the apoptosis of ECV304 cells. (C) Typical micrographs of invading ECV304 cells with different concentration of HGF. (D) HGF significantly increased the number of migrating cell at the concentration of 40 ng/mL. H0: without HGF, H20: with HGF (20 ng/mL), H40: with HGF (40 ng/mL). bP<0.05, cP<0.01 vs group without HGF.

One of the earliest steps in angiogenesis is the invasion of the basement membrane and migration of endothelial cells toward the angiogenic stimulants. In this study, we observed the effect of HGF on the migratory ability of ECV304 cells. Cells were incubated with HGF with a dose of 0, 20, or 40 ng/mL 3 h prior to irradiation with 20 Gy of gamma ray. At 48 h after irradiation, transwell chamber assay confirmed that the invasive and migratory ability of ECV304 cells was significantly increased by 3 h pre-incubation with HGF compared to without HGF (Figure 3C–3D).

Discussion

This study demonstrates that HGF may attenuate irradiation-induced damage of endothelial cells, thereby reducing the apoptosis and improving the proliferation and migration ability of endothelial cells.

As to pathogenesis of RIHD, some studies illustrate that myocardial degeneration and diffused fibrosis are preceded by irradiation-induced damage to the capillary network. Early morphological alterations in irradiated endothelial cells in vivo are irreversible and are followed by a persistent decrease in capillary density. Systematic morphometric studies in rats showed that the reduction of capillary volume, length and density sets in at about 20 days after heart irradiation, and its progress is dose dependent. Simultaneous with capillary rarefication is a focal loss of the endothelial cell marker enzyme alkaline phosphatase that increases with time. When the foci of myocardial degeneration developed, they were invariably situated within the areas of enzyme loss9, 25. Loss of enzyme activity was associated with foci of myocardial degeneration, supporting the hypothesis that lesions were secondary to vascular endothelial cells injury9.

HGF has mitogenic, morphogenic, and anti-apoptotic activities in a wide variety of cells. The potent activity of HGF to prevent cell death in distinct types of cells has been documented26, 27, 28. HGF has been shown to be released in response to myocardial ischemia-reperfusion injury29 and acute myocardial ischemia-reperfusion30, 31. It has been postulated that HGF serves as a cardioprotective agent in the heart32. Some of the cardioprotective effects of HGF may be due to its ability to induce angiogenesis by acting on vascular endothelial cells33.

Radiation injury to endothelial cells of the myocardial capillary network is the underlying cause of myocardial degeneration and heart failure after heart irradiation. In this study, the HGF receptor c-Met has been shown to be expressed in endothelial cells. We also found that c-Met can function through HGF-induced rapid tyrosine phosphorylation. Therefore, HGF can transmit signals that may protect endothelial cells against irradiation.

In this study, we irradiated ECV304 cells with gamma rays and found that gamma rays damaged the proliferation and migratory ability of ECV304 cells in a dose-dependent manner. Further, cells were incubated with HGF of different concentrations prior to irradiation. HGF was proven to increase the proliferation and inhibit the apoptosis of endothelial cells. We further evaluated the motility and invasive ability of endothelial cells. The invasive and migratory ability of ECV304 cells was significantly increased by 3 h pre-incubation with HGF prior to irradiation.

One of the earliest steps in angiogenesis is the invasion of the basement membrane and migration of endothelial cells toward the angiogenic stimulants. Angiogenesis is associated with viability and migratory ability of endothelial cells. This study demonstrated that HGF can attenuate radiation injury to endothelial cells, so these experimental results can lay a solid foundation for HGF therapy of irradiation-induced heart disease.

In summary, the present study demonstrates that endothelial cells have functional HGF/c-Met signaling machinery that exhibits phosphorylation of c-Met. Furthermore, the results of this study show that HGF can inhibit the apoptosis and promote the proliferation and motility of endothelial cells. HGF may be useful as a pharmacological agent to treat RIHD.

Author contribution

Hua WANG and Li-sheng WANG designed the research; Shun-ying HU, Hai-feng DUAN, Qing-fang LI, Yue-feng YANG and Jin-long CHEN performed the research. Shun-ying HU analyzed data and wrote the paper.

Acknowledgments

This project was supported in part by grants from International Atomic Energy Agency program (contract No 13305/R1) from National Mega-project of Science Research of China (No 2009ZX09503-019) and from China Postdoctoral Science Foundation (No 20080441309).

References

  1. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31:1205–11. doi: 10.1016/0360-3016(94)00656-6. [DOI] [PubMed] [Google Scholar]
  2. Schultz-Hector S, Sund M, Thames HD. Fractionation response and repair kinetics of radiation-induced heart failure in the rat. Radiother Oncol. 1992;23:33–40. doi: 10.1016/0167-8140(92)90303-c. [DOI] [PubMed] [Google Scholar]
  3. Gustavsson A, Eskilsson J, Landberg T, Svahn-Tapper G, White T, Wollmer P, et al. Late cardiac effect after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol. 1990;1:355–63. doi: 10.1093/oxfordjournals.annonc.a057774. [DOI] [PubMed] [Google Scholar]
  4. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11:1208–15. doi: 10.1200/JCO.1993.11.7.1208. [DOI] [PubMed] [Google Scholar]
  5. Reinders JJ, Heijmen BJ, Olofsen-van Acht MJ, van Putten WL, Levendag PC. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol. 1999;51:35–42. doi: 10.1016/s0167-8140(99)00026-2. [DOI] [PubMed] [Google Scholar]
  6. Early Breast Cancer Trialist's. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70. [PubMed] [Google Scholar]
  7. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206–14. doi: 10.1093/jnci/djk029. [DOI] [PubMed] [Google Scholar]
  8. Fajardo LF, Stewart JR. Experimental radiation-induced heart disease. Light microscopic studies. Am J Pathol. 1970;59:299–316. [PMC free article] [PubMed] [Google Scholar]
  9. Lauk S. Endothelial alkaline phosphatase activity loss as an early stage in the development of radiation-induced heart disease in rats. Radiat Res. 1987;110:118–28. [PubMed] [Google Scholar]
  10. Jaenke RS, Robbins MEC, Bywaters T, Whitehouse E, Rezvani M, Hopewell JW. Capillary endothelium. Target site if renal radiation injury. Lab Invest. 1993;68:396–405. [PubMed] [Google Scholar]
  11. Lauk S, Kiszel Z, Buschmann J, Trott KR. Radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys. 1985;11:801–8. doi: 10.1016/0360-3016(85)90314-1. [DOI] [PubMed] [Google Scholar]
  12. Schultz-Hector S, Balz K. Radiaton-induced loss of endothelial alkaline phosphatase activity and development of myocardial degeneration. An ultrastructural study. Lab Invest. 1994;71:252–60. [PubMed] [Google Scholar]
  13. Boerma M, Kruse JJ, van Loenen M, Klein HR, Bart CI, Zurcher C, et al. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol. 2004;180:109–16. doi: 10.1007/s00066-004-1138-0. [DOI] [PubMed] [Google Scholar]
  14. Wondergem J, van der Laarse A, van Ravels FJ, van Wermeskerken AM, Verhoeve HR, de Graaf BW, et al. In vitro assessment of cardiac performance after irradiation using an isolated working rat heart preparation. Int J Radiat Biol. 1991;59:1053–68. doi: 10.1080/09553009114550931. [DOI] [PubMed] [Google Scholar]
  15. Franken NA, Camps JA, van Ravels FJ. Comparison of in vivo cardiac function with ex vivo cardiac performance of the rat heart after thoracic irradiation. Br J Radiol. 1997;70:1004–9. doi: 10.1259/bjr.70.838.9404203. [DOI] [PubMed] [Google Scholar]
  16. Aoyama T, Takimoto Y, Pennica D, Inoue R, Shinoda E, Hattori R, et al. Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. T Mol Cell Cardiol. 2000;32:1821–30. doi: 10.1006/jmcc.2000.1218. [DOI] [PubMed] [Google Scholar]
  17. Schneider MD, Schwartz RJ. Chips ahoy: gene expression in failing hearts surveyed by high-density microarrays. Circulation. 2000;102:3026–7. doi: 10.1161/01.cir.102.25.3026. [DOI] [PubMed] [Google Scholar]
  18. Peterson D, Ju H, Hao J, Chapman DC, Dixon IM. Expression if Gia2 and Gsa in myofibroblasts localized to the infarct scar in heart failure due to myocardial infarction. Cardiovasc Res. 1998;41:575–85. doi: 10.1016/s0008-6363(98)00264-8. [DOI] [PubMed] [Google Scholar]
  19. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J cell Biol. 1995;129:1177–80. doi: 10.1083/jcb.129.5.1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci. 2008;13:7072–86. doi: 10.2741/3211. [DOI] [PubMed] [Google Scholar]
  21. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998;8:404–10. doi: 10.1016/s0962-8924(98)01359-2. [DOI] [PubMed] [Google Scholar]
  22. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–41. doi: 10.1083/jcb.119.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998;97:381–90. doi: 10.1161/01.cir.97.4.381. [DOI] [PubMed] [Google Scholar]
  24. Anki M, Morishta R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K, et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infracted myocardium; up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther. 2000;7:417–27. doi: 10.1038/sj.gt.3301104. [DOI] [PubMed] [Google Scholar]
  25. Fajardo LF, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest. 1973;29:244–57. [PubMed] [Google Scholar]
  26. Hu SY, Qiu L, Duan HF, Wang H, Wang RL, Guo ZK, et al. Hepatocyte growth factor protects cultured rat cardiomyocytes against apoptosis induced by gamma ray irradiation Med J Chin People Liberation Army 200732482–4.Chinese. [Google Scholar]
  27. Yo Y, Morishita R, Nakamura S, Tomita N, Yamamoto K, Moriguchi A, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on the epithelial cells. Kidney Int. 1998;54:1128–38. doi: 10.1046/j.1523-1755.1998.00092.x. [DOI] [PubMed] [Google Scholar]
  28. Kosai K, Matsumoto K, Nakamura T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology. 1999;30:151–9. doi: 10.1002/hep.510300102. [DOI] [PubMed] [Google Scholar]
  29. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation. 1997;95:2552–8. doi: 10.1161/01.cir.95.11.2552. [DOI] [PubMed] [Google Scholar]
  30. Matsumori A, Furukawa Y, Hashimoto T, Ono K, Shioi T, Okada M, et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun. 1996;221:391–5. doi: 10.1006/bbrc.1996.0606. [DOI] [PubMed] [Google Scholar]
  31. Sato T, Yoshinouchi T, Sakamoto T, Fujieda H, Murao S, Sato H, et al. Hepatocyte growth factor(HGF): a new biochemical marker for acute myocardial infarction. Heart Vessels. 1997;12:241–6. doi: 10.1007/BF02766790. [DOI] [PubMed] [Google Scholar]
  32. Schaper W, Kubin T. Is hepatocyte growth factor a protein with cardioprotective activity in the ischemic heart. Circulation. 1997;95:2471–2. doi: 10.1161/01.cir.95.11.2471. [DOI] [PubMed] [Google Scholar]
  33. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 1993;90:1937–41. doi: 10.1073/pnas.90.5.1937. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Acta Pharmacologica Sinica are provided here courtesy of Nature Publishing Group

RESOURCES